Illumina Ventures was among the returning investors for the round that will help Kallyope prepare a weight loss treatment for clinical trials.

Kallyope, a US-based developer of drugs for conditions related to the gut and brain, raised $112m yesterday in a series C round featuring Illumina Ventures, the investment arm of genomics technology producer Illumina. Alexandria Venture Investments, the venture capital unit of real estate investment trust Alexandria Real Estate Equities, also contributed to the round. The…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.